Albert Steven M, Li Xiaotong, Gill-Kane Sandra L, Lombardi Jacob, Akenapalli Krishi, Boyce Richard D
Department of Behavioral and Community Health Science, School of Public Health, Pittsburgh, Pennsylvania, USA.
Department of Pharmacy and Therapeutics, School of Pharmacy, Pittsburgh, Pennsylvania, USA.
J Am Geriatr Soc. 2025 Mar;73(3):728-736. doi: 10.1111/jgs.19340. Epub 2024 Dec 31.
The incidence of potentially inappropriate medication (PIM) prescribing among older adults is not as well studied as its prevalence. Estimates of factors associated with PIM incidence, such as patient age, sex, race-ethnicity, medication subsidy support, and comorbidity, are also limited.
To estimate the incidence of PIM prescribing in older adult outpatients, as well as the incidence and predictors for each PIM class, in a large outpatient electronic health records (EHR) cohort.
Retrospective study of PIM prescribing among outpatients with encounters leading to prescription orders, 2015-2018, excluding prevalent cases.
Outpatients receiving care from a multi-site health system in western Pennsylvania.
342,405 patients, contributing 893,754 person-years of follow-up.
The incidence of PIM prescribing based on automated coding of 2019 Beers criteria. A multivariable Poisson regression model was estimated to assess the impact of age, sex, race-ethnicity, comorbidity, and medication subsidy (PACE/PACENET) on PIM risk. For each PIM class, the association between predictors and time to PIM prescribing was evaluated using proportional hazard models.
The incidence rate (IR) for 1 or more PIM was 193.5 per 1000 person-years, led by short- and intermediate-acting benzodiazepines (37.6), first-generation antihistamines (32.8), and skeletal muscle relaxants (22.0). The incidence of PIM prescribing was 15% higher among white patients and 35% lower among males. High comorbidity (Charlson score ≥ 3) was associated with a 59% higher risk. Participation in the PACE/PACENET program, a medication subsidy program, was associated with an 83% increase in incidence. Each additional year of age was associated with a 1.2% reduction in incidence.
This study establishes benchmarks for the incidence of PIM prescribing in outpatients and identifies important disparities in PIM risk, which vary by PIM class.
老年人中潜在不适当用药(PIM)处方的发生率不如其流行率那样得到充分研究。与PIM发生率相关的因素估计,如患者年龄、性别、种族、药物补贴支持和合并症等,也很有限。
在一个大型门诊电子健康记录(EHR)队列中,估计老年门诊患者中PIM处方的发生率,以及每种PIM类别(发生)的发生率和预测因素。
对2015 - 2018年有导致处方医嘱诊疗经历的门诊患者中PIM处方进行回顾性研究,排除现患病例。
在宾夕法尼亚西部一个多地点医疗系统接受治疗的门诊患者。
342,405名患者,提供了893,754人年的随访数据。
基于2019年Beers标准自动编码的PIM处方发生率。估计一个多变量泊松回归模型,以评估年龄、性别、种族、合并症和药物补贴(PACE/PACENET)对PIM风险的影响。对于每种PIM类别,使用比例风险模型评估预测因素与PIM处方发生时间之间的关联。
1种或更多种PIM的发生率(IR)为每1000人年193.5例,以短效和中效苯二氮䓬类药物(37.6)、第一代抗组胺药(32.8)和骨骼肌松弛剂(22.0)为主。白人患者中PIM处方发生率高15%,男性中低35%。高合并症(Charlson评分≥3)与风险高59%相关。参与PACE/PACENET项目(一个药物补贴项目)与发生率增加83%相关。年龄每增加一岁,发生率降低1.2%。
本研究为门诊患者中PIM处方发生率确立了基准,并识别出PIM风险方面的重要差异,这些差异因PIM类别而异。